About IASO
Jinhua Zhang
Founder, Chairman, and CEO
Accolades
Selected for the 2024 China's New Drug Pioneer Award 20 Years 20 People.
Selected for the 2024 Fortune China's Most Powerful Women in Business Future List.
Ms. Jinhua Zhang has over 20 years of experience in securities market and corporate management. Prior to founding IASO Bio, she worked in investment banks and leading securities law firms, where she led overseas and domestic listing and M&A restructuring projects for many Chinese companies. She also previously invested as an angel investor in cell therapy startups and served as director.
Drawing on her extensive background in IPOs, mergers and acquisitions and investments in the biopharmaceutical field, Ms. Zhang founded IASO Bio in March 2017 with the vision of ''focusing on innovative biotherapies to bring hope of cure to patients''. Under her leadership, IASO Bio has grown into a leader in the cell therapy sector, with end-to-end capabilities across discovery, development, manufacturing and commercialization. The company successfully launched its blockbuster CAR-T product, Fucaso in 2023.
Ms. Zhang obtained her bachelor's degree in laws, and master's degree in laws, both majoring in economic law, from Dongbei University of Finance and Economics.